Wednesday, September 24, 2025 Hematology Cohort study - Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemiaResearchers conducted a population-based cohort study of Ontario residents aged ≥66 years who initiated ibrutinib for chronic lymphocytic leukaemia (CLL) to evaluate the frequency of potential drug interactions involving moderate/strong CYP3A inhibitors and inducers and their association with overall survival (OS). Hoang T, Cheung MC, Juurlink DN, Chan KKW, Lau C, Liu N, Abdel-Qadir H, Prica A, Hay AE, Vijenthira A, Mozessohn L. Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia (ONLINE). British Journal of Haematology 2025.https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.70131 MA20 Sub study - Prognostic and predictive capacity of tumor infiltrating lymphocytes in the MA.20 regional node radiotherapy trialHigh levels of stromal tumor-infiltrating lymphocytes (sTILs) reflect the robustness of host anti-tumor immunity in most solid organ malignancies, including breast cancer1. Assessment of sTILs on hematoxylin and eosin (H&E) stained sections has shown reliability, reproducibility, and feasibility as a validated biomarker for gauging pre-existing anti-tumoral immunity using readily available and inexpensive methodologies. Riaz N, Chen BE, Bane A, Gao D, Stovgaard ES, Kos Z, Leung SC, Shenasa E, Parulekar W, Chambers S, Nielsen TO, Whelan TJ. Prognostic and predictive capacity of tumor infiltrating lymphocytes in the MA.20 regional node radiotherapy trial. npj Breast Cancer 11: 97. 2025.https://doi.org/10.1038/s41523-025-00821-z
